Group items tagged

A key strategic focus of the SickKids Research Institute is the commercialization of research findings-translating discoveries into new technologies and treatments to improve the understanding and treatment of diseases that affect children.

"An environment like the Discovery District allows research institutes and the University of Toronto and its affiliated hospitals to work together to promote research and its application," she explains.

One of the unique aspects of Toronto is its open, collaborative environment. Individual institutes are not fighting each other for funding resources. This collaborative nature is what people comment on when they come here." A Toronto location provides other advantages too, she says. "There is a strong university and college environment, which provides a great pool from which to draw talent. There is strong support from all three levels of government. And there is strong philanthropic support, which is important." Dr. Rossant says working for the Hospital for Sick Children has been very gratifying.

Dr. Rossant is also looking forward to the opening of the new research and education building going up in the Discovery District. "The Research Institute currently has 2,000 people spread across the Discovery District and the new building will bring us all together and allow us to interact in new ways."

A good example of where both business and health-care expertise is needed is at Crown agencies such as eHealth Ontario.

The new Ivey centre builds on a partnership with the London Health Sciences Centre and the Schulich School of Medicine and Dentistry

W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto

MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.

The goal is to make cells that can replace tissue damaged by disease or accidents, with Sick Kids researchers particularly interested in cystic fibrosis and autism, a government source said.

“Collaboration is the essence of the new economy,” insists Ross Wallace, director of strategic partnerships at MaRS. “There’s a new focus on the power of institutions to generate intellectual property and ideas, and then build around them.”

MaRS has a virtual education program dubbed “Entrepreneurship 101.” One February class features budgeting, another agrifood innovation. The classes are available at no cost, and anyone can register. The program also includes blogs and discussion groups such as the drug development and cancer targets groups. So far, MaRS has relied on viral marketing to get the word out.

To provide that expertise, MaRS developed the MaRS Venture Group. This team of experienced investors, entrepreneurs, technology experts, and advisors works with companies to help them bridge the gap between entrepreneurial start-up and experienced growth company. The Venture Group provides market intelligence as well  as advisory services such as strategic planning, partnership and alliance building, intellectual property management, marketing and communications, sales strategy, channel development, financing, and human resource development. It works with groups outside the MaRS orbit, too.